Sign In to Follow Application
View All Documents & Correspondence

Therapeutic Composition For Alzheimer''S Disease

Abstract: [0037] The present invention relates to a composition comprising of EGCG, the active component extracted from green tea leaves and nutritional supplement such as Chromium polynicotinate for treating Alzheimer’s disease by arresting formation of beta amyloid proteins. Concentration of EGCG in the composition is at least 90% EGCG and ensures that the bioavailability of the product is extremely high.

Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence

Patent Information

Application #
Filing Date
04 July 2012
Publication Number
34/2016
Publication Type
INA
Invention Field
PHARMACEUTICALS
Status
Email
Parent Application

Applicants

NUTRI SYNAPZZ THERAPEUTIX PRIVATE LIMITED
NO. 203, 2ND FLOOR, BEML, IVTH STAGE, RAJA RAJESHWAR NGAR, BANGALROE - 650 098

Inventors

1. SRIKANTAN NIRANJAN
C/O NUTRI SYNAPZZ THERAPEUTIX PRIVATE LIMITED NO 203, ND FLOOR, BEML, IVTH STAGE, RAJA RAJESJWARI NAGAR, BANGALROE - 560 098

Specification

DESC:as attached ,CLAIMS:What is claimed is
1. A composition for treating Alzheimer’s disease, the composition comprising:
a therapeutically effective amount of Epigallocatechin Gallate (EGCG) that cures the disease by preventing beta amyloid plaque formation in brain;
a therapeutically effective amount of chromium polynicotinate.
2. The composition according to claim 1, wherein the EGCG component of composition is extracted from green tea.
3. The composition according to claim 1, wherein the composition is in form of capsule or syrup or tablet for oral administration.
4. The composition according to claim 1, wherein the EGCG is the ester of epigallocatechin and gallic acid.
5. The composition according to claim 1, wherein the composition also increases tyrosine kinase activity to produce ATP to rejuvenate neurons.
6. The composition according to claim 1, wherein the chromium polynicotinate component of said composition increases glucose metabolism in brain.
7. The composition according to claim 1, wherein the composition treats said disease by promoting non amyloidogenic processing of amyloid precursor protein by up regulating beta secratase or normalize beta secratase production so that amyloid protein is not produced at all.

Documents

Application Documents

# Name Date
1 2687-CHE-2012 POWER OF ATTORNEY 04-07-2012.pdf 2012-07-04
2 2687-CHE-2012 FORM-2 04-07-2012.pdf 2012-07-04
3 2687-CHE-2012 FORM-1 04-07-2012.pdf 2012-07-04
4 2687-CHE-2012 DESCRIPTION (PROVISIONAL) 04-07-2012.pdf 2012-07-04
5 2687-CHE-2012 CORREPONDENCE OTHERS 04-07-2012.pdf 2012-07-04
6 Form 5.pdf 2013-07-05
7 Complete specification.pdf 2013-07-05
8 2687-CHE-2012 FORM-3 23-07-2013.pdf 2013-07-23
9 2687-CHE-2012 CORRESPONDENCE OTHERS 23-07-2013.pdf 2013-07-23
10 2687-CHE-2012-FER.pdf 2018-01-17
11 2687-CHE-2012-AbandonedLetter.pdf 2018-08-28

Search Strategy

1 2687_03-01-2018.pdf